Journal of Clinical and Experimental Hepatology最新文献

{"title":"Issue Highlights","authors":"","doi":"10.1016/S0973-6883(24)01144-7","DOIUrl":"10.1016/S0973-6883(24)01144-7","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 1","pages":"Article 102477"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143163429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MASLD, MLA Pesarattu and Other Developments","authors":"Anil C. Anand","doi":"10.1016/j.jceh.2024.102465","DOIUrl":"10.1016/j.jceh.2024.102465","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 1","pages":"Article 102465"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of the ASAP Score for Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1,239 Patients","authors":"Tian Yang ,&nbsp;Dong-Xu Yin ,&nbsp;Yong-Kang Diao ,&nbsp;Ming-Da Wang ,&nbsp;Xian-Ming Wang ,&nbsp;Yong-Yi Zeng ,&nbsp;Zhong Chen ,&nbsp;Han Liu ,&nbsp;Fu-Jie Chen ,&nbsp;Yu-Chen Li ,&nbsp;Jia-Hao Xu ,&nbsp;Han Wu ,&nbsp;Lan-Qing Yao ,&nbsp;Xin-Fei Xu ,&nbsp;Chao Li ,&nbsp;Li-Hui Gu ,&nbsp;Alfred W. Chieh Kow ,&nbsp;Timothy M. Pawlik ,&nbsp;Feng Shen","doi":"10.1016/j.jceh.2024.102497","DOIUrl":"10.1016/j.jceh.2024.102497","url":null,"abstract":"<div><h3>Background and aims</h3><div>The ASAP score, which incorporates age, sex, alpha-fetoprotein (AFP), and protein induced by vitamin K absence-II, has demonstrated promise for early detection of hepatocellular carcinoma (HCC). However, its prognostic value after HCC treatment remains unknown. The current study sought to evaluate the prognostic value of the ASAP score to predict recurrence and survival following curative hepatic resection for HCC.</div></div><div><h3>Methods</h3><div>This study using prospectively collected data included HCC patients who underwent curative-intent hepatic resection. The ASAP score was calculated preoperatively, and X-tile analysis was used to determine the optimal cutoff value. Univariate and multivariate analyses were performed to identify independent risk factors associated with recurrence and overall survival (OS).</div></div><div><h3>Results</h3><div>Among 1239 patients in the analytic cohort, the optimal ASAP score cutoff was 4.8; patients were divided into low (n = 749) and high (n = 490) ASAP score subgroups. Patients with high ASAP scores had a higher incidence of 5-year recurrence (73.9% vs 51.0%, <em>P</em> &lt; 0.001) and worse OS (31.7% vs 60.1%, <em>P</em> &lt; 0.001) versus individuals with low scores. Multivariate analysis identified ASAP score ≥4.8 as an independent risk factor of both recurrence (hazard ratio [HR] 1.976, 95% confidence interval [CI]: 1.633–2.390, <em>P</em> &lt; 0.001) and OS (HR 1.407, 95% CI 1.170–1.691, <em>P</em> &lt; 0.001) after controlling for established clinicopathological factors.</div></div><div><h3>Conclusion</h3><div>Preoperative ASAP score was independently associated with recurrence and survival after HCC resection. The clinical utility of the ASAP score may be applicable to both diagnosis and prognosis, potentially improving postoperative surveillance and management strategies for HCC patients.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102497"},"PeriodicalIF":3.3,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced Autoimmune-like Hepatitis With Pathological Features of Giant Cell Hepatitis","authors":"Jie Yao ,&nbsp;Yongqin Yan,&nbsp;Mei Ruan,&nbsp;Haiyan Lin,&nbsp;Dongliang Li,&nbsp;Zhiyu Zeng","doi":"10.1016/j.jceh.2024.102498","DOIUrl":"10.1016/j.jceh.2024.102498","url":null,"abstract":"<div><h3>Background and methods</h3><div>The differentiation between drug-induced autoimmune-like hepatitis (DI-ALH) and autoimmune hepatitis (AIH) can be confusing and challenging. We present a case of DI-ALH characterized by positive autoantibodies, elevated immunoglobulin G (IgG) levels and histology characteristics of giant cell hepatitis.</div></div><div><h3>Results</h3><div>A liver biopsy was performed for etiology clarification, DI-ALH was diagnosed. Following treatment with corticosteroids and azathioprine, the patient's liver function remained normal without recurrence.</div></div><div><h3>Conclusions</h3><div>Distinguishing DI-ALH from AIH based on the possibility of discontinuing immunosuppression and the histological features. Clinicians need to investigate patient's medical history, serological tests, and pathological changes to establish a correct diagnosis.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102498"},"PeriodicalIF":3.3,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis","authors":"Matheus Souza ,&nbsp;Lubna Al-Sharif ,&nbsp;Ivanna Diaz ,&nbsp;Alessandro Mantovani ,&nbsp;Cristiane Alves Villela-Nogueira","doi":"10.1016/j.jceh.2024.102495","DOIUrl":"10.1016/j.jceh.2024.102495","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div><em>PNPLA3</em> rs738409 variant is a risk factor for onset and progression of metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to assess its global prevalence, clinical and histological characteristics, and long-term outcomes in patients with MASLD.</div></div><div><h3>Methods</h3><div>PubMed and Embase databases were searched until December 30, 2023, for observational studies on <em>PNPLA3</em> genotyped adults with MASLD. Proportions were pooled using a generalized linear mixed model with Clopper–Pearson intervals. Continuous and dichotomous variables were analyzed using the DerSimonian–Laird method. International Prospective Register of Systematic Reviews registration number: CRD42023449838.</div></div><div><h3>Results</h3><div>A total of 109 studies involving 118,302 individuals with MASLD were identified. The overall minor allele frequency of the G allele [MAF(G)] at <em>PNPLA3</em> was 0.45 (95% confidence interval [CI]: 0.43; 0.48) with high heterogeneity (I² = 98%). The highest MAF(G) was found in Latin America (0.63) and the lowest in Europe (0.38). No African countries were identified. Carriers of the <em>PNPLA3</em> variant had reduced adiposity, altered fat metabolism, and worse liver damage/histology than noncarriers. There was significant heterogeneity in the clinical/histological analyses (I² &gt; 50%). Only the <em>PNPLA3</em> GG genotype was associated with higher mortality and liver-related events with no heterogeneity (I² = 0%). Metaregressions showed the influence of adiposity, age, diabetes mellitus, and glucose on some <em>PNPLA3</em> expression parameters. Overall, there was a moderate risk of bias in the included studies.</div></div><div><h3>Conclusions</h3><div>This study reveals the global pattern of <em>PNPLA3</em> and its clinical, histological, and outcome implications in MASLD. Patients with MASLD and <em>PNPLA3</em> variant have different clinical features and worse liver severity, and only <em>PNPLA3</em> GG has a higher risk of mortality and liver outcomes. Our findings highlight the importance of <em>PNPLA3</em> genotyping in clinical trials and advocate for personalized medicine approaches.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102495"},"PeriodicalIF":3.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Acute Kidney Injury (AKI) Biomarkers FABP1, NGAL, Cystatin C and IL-18 in an Indian Cohort of Hospitalized Acute-on-chronic Liver Failure (ACLF) Patients","authors":"Rohini Saha ,&nbsp;Samriddhi Sharma ,&nbsp;Antara Mondal ,&nbsp;Hem C. Sati ,&nbsp;Maroof A. Khan ,&nbsp;Sandeep Mahajan ,&nbsp;Sudip Datta ,&nbsp;Shalimar ,&nbsp;Pragyan Acharya","doi":"10.1016/j.jceh.2024.102491","DOIUrl":"10.1016/j.jceh.2024.102491","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis associated with systemic inflammation and organ dysfunction. In ACLF, the development of acute kidney injury (AKI) is associated with poor outcomes. FABP1, NGAL, Cys C and IL-18 have been shown to correlate with ACLF severity and mortality. Hence, our study aimed to evaluate the association of these biomarkers with organ dysfunctions, particularly AKI, in an Indian ACLF patient cohort.</div></div><div><h3>Methods</h3><div>151 study participants including ACLF (n = 91; with AKI n = 63, no-AKI n = 28), non-liver AKI (n = 30) and healthy controls (n = 30) were recruited. Serum ELISA was performed for biomarker estimation. Data interpolation and graphical representation were performed using GraphPad Prism and statistical analyses performed using STATA 14.0.</div></div><div><h3>Results</h3><div>FABP1 and Cys C levels were higher in ACLF-AKI patients compared to ACLF no-AKI (<em>P</em>-value ≤ 0.0005). Serum Cys C levels were significantly increased in non-liver AKI compared to ACLF-AKI (<em>P</em>-value ≤ 0.001). AUROC analysis showed better performance of Cys C (AUC 0.79; 95% CI (0.68–0.89)) compared to serum creatinine (AUC 0.71; 95% CI (0.61–0.82)) in discriminating AKI and no-AKI. Correlation analysis revealed positive correlations of FABP1 with creatinine and urea, Cys C with creatinine, urea and OF-Kidney, NGAL, and IL-18 with general markers of organ dysfunction. Plasma MTs) measured in a subset of ACLF patients were elevated in progression-to-AKI.</div></div><div><h3>Conclusion</h3><div>Our study showed that in an Indian population of ACLF patients with a high short-term mortality, serum Cys C and FABP1 were elevated in ACLF-AKI, however did not have predictive potential for ACLF-AKI. Cys C levels were significantly higher in non-liver AKI patients vs. ACLF-AKI and correlated with markers of kidney dysfunction whereas NGAL and IL-18 represented higher inflammation and total organ dysfunction. Hence, we conclude that these biomarkers were elevated in ACLF-AKI but did not have predictive potential for AKI in ACLF.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102491"},"PeriodicalIF":3.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD)","authors":"Wesley Dixon ,&nbsp;Kathleen E. Corey ,&nbsp;Jay Luther ,&nbsp;Russell P. Goodman ,&nbsp;Esperance A. Schaefer","doi":"10.1016/j.jceh.2024.102492","DOIUrl":"10.1016/j.jceh.2024.102492","url":null,"abstract":"<div><h3>Background</h3><div>Recent introduction of new steatotic liver disease categorizations has necessitated updated epidemiologic studies. Specifically, recognition of (1) “MetALD” defined as where metabolic dysfunction–associated steatotic liver disease (MASLD) overlaps with alcohol use and (2) alcohol-related liver disease (ALD) without cardiometabolic risk factors (CMRFs) creates new clinical phenotypes with undefined prevalence.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional multicenter analysis of liver disease associated with alcohol use (ALD and MetALD). We included adults with an International Classification of Diseases (ICD) diagnosis of ALD or both metabolic dysfunction associated liver disease and alcohol use disorder assigned from 1/1/2000–1/1/2024.</div></div><div><h3>Results</h3><div>Among 4057 patients, only 118 (2.9%) did not have any CMRF (“pure ALD”). Compared to patients with CMRF, patients with pure ALD were more commonly female (56% [0 CRMF] vs. 48%, 45%, 38%, and 42% [1, 2, 3, and 4 CMRFs, respectively]; <em>P</em> &lt; 0.01) and younger (54 vs. 53, 60, 68, and 67 years [1, 2, 3, and 4 CMRFs, respectively]; <em>P</em> &lt; 0.01). Those with pure ALD had higher rates of cirrhosis (49% vs. 39%, 31%, 30%, 34% [1, 2, 3, and 4 CMRFs, respectively]; <em>P</em> &lt; 0.01), hepatocellular carcinoma (10% vs. 6.9%, 5.7%, 4.3%, and 5.1% [1, 2, 3, and 4 CMRFs, respectively]), and death (21% vs. 15%, 17%, 18%, and 21% [1, 2, 3, and 4 CMRFs, respectively]; <em>P</em> = 0.04). Patients whose only CMRF was body mass index (BMI) 25–30 kg/m² did not differ significantly from patients with pure ALD. Factors associated with cirrhosis in univariable analysis included male sex (odds ratio [OR]: 1.47, confidence interval [CI]: 1.29–1.67), age (OR: 1.08 per 10 years, CI: 1.03–1.13), and diabetes (OR: 1.21, CI: 1.05–1.40) but not BMI 25–30 kg/m² (OR: 0.86, CI: 0.64–1.14). No differences in single-nucleotide polymorphisms (<em>PNPLA3, GCKR, TM6SF2, MBOAT7,</em> or <em>HSD17B12</em>) were identified between groups.</div></div><div><h3>Conclusions</h3><div>ALD without diagnosed metabolic disease is uncommon and associated with higher rates of cirrhosis, HCC, and all-cause mortality than ALD with concurrent CMRF. Having a BMI measuring 25–30 kg/m² did not impact these clinical outcomes, raising the question of optimal BMI cut-off for MetALD. Further investigating these novel disease categories is essential for better understanding their biology and clinical impact.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102492"},"PeriodicalIF":3.3,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Locoregional Therapy on Survival After Living Donor Liver Transplantation for Hepatocellular Carcinoma--Experience from a High-volume Center","authors":"Vibha Varma,&nbsp;Phani K. Nekarakanti,&nbsp;Shaleen Agarwal,&nbsp;Rajesh Dey,&nbsp;Subash Gupta","doi":"10.1016/j.jceh.2024.102490","DOIUrl":"10.1016/j.jceh.2024.102490","url":null,"abstract":"<div><h3>Background</h3><div>Locoregional therapy (LRT) in patients with hepatocellular carcinoma (HCC) before liver transplantation (LT) has a role in improving the tumor biology and post-LT survival outcome apart from downstaging and bridging. We retrospectively analyzed our database of adult living donor liver transplants (LDLT) for HCC, to compare the survival outcomes in Group-1 (upfront-LT, HCC within Milan/UCSF/AFP&lt;1000 ng/ml) and Group-2 (LT post-LRT, HCC beyond UCSF/irrespective of tumor burden with AFP&gt;1000 ng/ml). We also explored the risk factors for recurrence on follow-up.</div></div><div><h3>Methods</h3><div>A study group (n = 506, Group-1-348, Group-2 = 158) of patients with HCC who underwent LDLT between July 2006 and December 2022, excluding incidental HCC (n = 42), patients with other histology (n = 13) and in-hospital mortality (n = 43), were analyzed. Study cohort (n = 341), after propensity score matching, was analyzed for survival outcomes (overall survival, OS and disease-free survival, DFS) and risk factors for recurrence between Group-1 (n = 156) and Group-2 (n = 158).</div></div><div><h3>Results</h3><div>Group-2 exhibited a trend towards better mean OS and DFS compared to Group-1 (OS-133 vs. 107-months, <em>P</em> = NS, DFS-118 vs. 102-months, <em>P</em> = NS). Long-term OS (10-year) for those within Milan and UCSF criteria was superior in Group-2, <em>P</em> = NS. Complete pathological response (cPR) after LRT (46.8%), significantly improved OS and DFS compared to those with partial response and stable disease; 152 vs. 94 vs. 49 months, <em>P</em> = 0.001, and 147 vs. 75 vs. 41 months, <em>P</em> = 0.006, respectively. Recipient age, size of tumor, and pre-LT serum alpha-fetoprotein (AFP) were independent predictors of cPR. Independent risk factors for recurrence included pre-LT AFP, tumors beyond UCSF, perineural invasion, and high-grade tumors.</div></div><div><h3>Conclusion</h3><div>Locoregional therapy in HCC offers significantly better OS and DFS in those who had a complete pathological response. Risk factors for recurrence post-LT were AFP level, beyond UCSF tumors, and high-grade HCC with PNI on histology.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102490"},"PeriodicalIF":3.3,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Survival and Recurrence in HCC vs. Non-HCC Liver Transplant Recipients: A Two-Decade Longitudinal Analysis","authors":"Mahmoudreza Moein ,&nbsp;Bridgette Nixon ,&nbsp;Michael Leyderman ,&nbsp;Ali Bassir ,&nbsp;Brenden Maloney ,&nbsp;Abolfazl Jamshidi ,&nbsp;Matin Moallem Shahri ,&nbsp;Amin Bahreini ,&nbsp;Alireza Golkarieh ,&nbsp;Reza Saidi","doi":"10.1016/j.jceh.2024.102489","DOIUrl":"10.1016/j.jceh.2024.102489","url":null,"abstract":"<div><h3>Background</h3><div>We aim to compare the long-term survival outcomes of patients who have received liver transplants (LTs) as a result of primary hepatocellular carcinoma (HCC).</div></div><div><h3>Methods and materials</h3><div>A retrospective registry analysis of the Scientific Registry of Transplant Recipients (SRTR) database was done for LTs that were performed in the United States from January 2000 to June 2023.</div></div><div><h3>Results</h3><div>A total of 143,717 LT cases have met both the inclusion and the exclusion criteria and were included in the final analysis. The most common primary diagnosis in the non-HCC cohort was hepatitis C virus (HCV) (14,813 cases, 27%), alcoholic cirrhosis (6631 cases, 12.1%) in the 2001–2010 cohort, alcoholic cirrhosis (18,370 cases, 20.7%), and non-alcoholic steatohepatitis (NASH) (13,997 cases,15.8%) in the 2011–2023 cohort. The data analysis showed a significant overall one- and five-year allograft survival improvement in the 2011–2023 time frame compared to the 2001–2010 group in both HCC and non-HCC patients. The allograft survival difference became more significant after the 5 years of follow-up with a 10% difference between the two time frames in both HCC and non-HCC groups. Patients who met and were selected based on Milan's criteria had significantly better outcomes in both cohorts. Five-year allograft and patient survival were also significantly higher in the patients who met Milan's criteria in 2011–2023 cohort, compared to 2001–2010 cohort (74.4% vs. 66.1%, <em>P</em>-value &lt;0.001, and 76% vs. 68.7%, <em>P</em>-value &lt;0.01, respectively). Acute and chronic rejections were significantly higher in the non-HCC groups in both time frames. It was 6.5% vs. 4.8%, <em>P</em> = 0.03 in 2001–2010, and 13.6% vs. 8.2%, <em>P</em> = 0.0007 in 2011–2023, for acute rejection and 10.8% vs. 6.7%, <em>P</em> = 0.0001 in 2001–2010, and 14.1% vs. 10.3%, <em>P</em> = 0.01 in 2011–2023, for chronic rejection.</div></div><div><h3>Conclusion</h3><div>Short- and long-term outcomes of LT are almost equal to the other causes of liver transplantation in the recent decade, which can significantly overcome the dilemma of doing LT in patients with HCC diagnosis, who need LT. Adhering to the Milan criteria is crucial for optimizing outcomes, as demonstrated by our study's findings, which highlight significantly better allograft and patient survival rates among those who meet these criteria.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102489"},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response and Adverse Event Rates With Placebo in Compensated MASH-related Cirrhosis: A Meta-analysis","authors":"Marcio J.M. Amaral,&nbsp;Felipe S. Moura,&nbsp;Luan C.V. Lima,&nbsp;Matheus Souza","doi":"10.1016/j.jceh.2024.102487","DOIUrl":"10.1016/j.jceh.2024.102487","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 3","pages":"Article 102487"},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}